Nexgel Inc (NXGL)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $2.08M
Last updated: Nov 17, 2026 at 10:58 AM ET
Nexgel Inc (NXGL) Earnings: Report Dates and Results
Nexgel (NXGL) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Nexgel reported EPS of -$1.60, above the -$4.80 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NXGL has an expected report date of Mar 29, 2027.
NXGL Earnings Call
The latest NXGL earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 21 quarters below that had an estimate, NXGL beat 5, missed 15 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $3.18M, up 8.5% from $2.93M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.60 | -$4.80 | -$4.80 - -$4.80 | +66.67% | Beat | N/A | 1 | 0 up, 1 down | Nov 10, 2026 | $3.18M |
| Jun 30, 2026 | -$0.40 | -$0.12 | -$0.12 - -$0.12 | -233.33% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2026 | $3.69M |
| Mar 31, 2026 | -$0.11 | -$0.07 | -$0.07 - -$0.07 | -57.14% | Miss | N/A | 1 | 0 up, 0 down | May 13, 2026 | $2.65M |
| Dec 31, 2025 | -$0.15 | -$0.03 | -$0.03 - -$0.03 | -396.00% | Miss | N/A | 1 | 0 up, 1 down | Mar 31, 2026 | $2.80M |
| Sep 30, 2025 | -$0.08 | -$0.08 | -$0.08 - -$0.08 | 0.00% | In line | N/A | 1 | 0 up, 1 down | Nov 11, 2025 | $2.93M |
| Jun 30, 2025 | -$0.10 | -$0.07 | -$0.07 - -$0.07 | -42.86% | Miss | N/A | 1 | 0 up, 1 down | Aug 12, 2025 | $2.88M |
| Mar 31, 2025 | -$0.09 | -$0.10 | -$0.10 - -$0.10 | +10.00% | Beat | N/A | 1 | 0 up, 0 down | May 13, 2025 | $2.81M |
| Dec 31, 2024 | -$0.11 | -$0.10 | N/A | -10.00% | Miss | N/A | 1 | 0 up, 1 down | Mar 24, 2025 | $3.04M |
| Sep 30, 2024 | -$0.11 | -$0.10 | -$0.10 - -$0.10 | -10.00% | Miss | N/A | 1 | 1 up, 0 down | Nov 13, 2024 | $2.94M |
| Jun 30, 2024 | -$0.15 | -$0.14 | -$0.14 - -$0.14 | -7.14% | Miss | N/A | 1 | 0 up, 0 down | Aug 19, 2024 | $1.44M |
| Mar 31, 2024 | -$0.14 | -$0.18 | -$0.18 - -$0.18 | +22.22% | Beat | N/A | 1 | 0 up, 0 down | Apr 1, 2024 | $1.27M |
| Dec 31, 2023 | -$0.21 | -$0.11 | -$0.11 - -$0.11 | -90.91% | Miss | N/A | 1 | 0 up, 0 down | Mar 18, 2024 | $1.08M |
| Sep 30, 2023 | -$0.11 | -$0.12 | N/A | +8.33% | Beat | N/A | N/A | N/A | Nov 13, 2023 | $1.22M |
| Jun 30, 2023 | -$0.14 | -$0.13 | N/A | -7.69% | Miss | N/A | N/A | 0 up, 0 down | Aug 14, 2023 | $1.17M |
| Mar 31, 2023 | -$0.16 | -$0.14 | N/A | -14.29% | Miss | N/A | N/A | 0 up, 0 down | May 15, 2023 | $620000 |
| Dec 31, 2022 | -$0.11 | -$0.15 | -$0.15 - -$0.15 | +26.67% | Beat | N/A | 1 | 0 up, 0 down | Mar 27, 2023 | $523000 |
| Sep 30, 2022 | -$0.21 | -$0.13 | N/A | -61.54% | Miss | N/A | N/A | 0 up, 0 down | Nov 8, 2022 | $568000 |
| Jun 30, 2022 | -$0.19 | -$0.15 | -$0.15 - -$0.15 | -26.67% | Miss | N/A | 1 | 0 up, 0 down | Aug 10, 2022 | $561000 |
| Mar 31, 2022 | -$0.28 | -$0.15 | -$0.15 - -$0.15 | -86.67% | Miss | N/A | 1 | 0 up, 0 down | May 12, 2022 | $396000 |
| Dec 31, 2021 | -$0.52 | -$0.37 | N/A | -40.54% | Miss | N/A | N/A | N/A | Mar 21, 2022 | $532000 |
| Sep 30, 2021 | -$0.21 | -$0.20 | N/A | -5.00% | Miss | N/A | N/A | N/A | Nov 10, 2021 | $335000 |
| Jun 30, 2021 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 16, 2021 | $417000 |
| Mar 31, 2021 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 17, 2021 | $267000 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.42, after -$0.51 the year before. It was -$1.01 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.42 | N/A |
| Dec 31, 2024 | -$0.51 | N/A |
| Dec 31, 2023 | -$0.62 | N/A |
| Dec 31, 2022 | -$0.79 | N/A |
| Dec 31, 2021 | -$1.01 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,600 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 2,633 | 6 | |
| 2025Q4 | Dec 31, 2025 | 3,710 | 9 | |
| 2025Q3 | Sep 30, 2025 | 3,013 | 6 | |
| 2025Q2 | Jun 30, 2025 | 4,866 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,064 | 7 | |
| 2024Q3 | Sep 30, 2024 | 3,876 | 7 | |
| 2024Q2 | Jun 30, 2024 | 2,817 | 6 |
2026Q1 Earnings Call
Opening remarks
Valter Pinto Managing Director, KCSA Strategic Communications Thank you, operator. Good afternoon, and welcome, everyone, to NEXGEL's shareholder update conference call. I am joined today by Adam R. Levy, Chief Executive Officer. Before we begin, I would like to remind everyone that statements made during today's conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of risks, uncertainties, and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to our filings with the SEC filed periodically. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, unless otherwise required by law. With that, it is my pleasure to turn the call over to Mr. Adam R. Levy. Adam, please go ahead.
Adam R. Levy Chief Executive Officer Thank you, Valter, and thank you, everyone, for joining us today. On today's call, I would like to provide an overview of our first quarter 2026 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid-April. Starting with our first quarter results, revenue for the first quarter totaled $2.65 million as compared to $2.81 million for the same period last year. The business year-over-year was relatively flat, with sales from Silly George coming in lower, which were partially offset by revenue growth in both contract manufacturing and our MEDAGEL brand. During the quarter, the increase in our SG&A was due primarily to costs incurred relating to the acquisition of our BioNX division and the KISS Nail Products legal case which has since been settled. Cash and restricted cash as of 03/31/2026 was approximately $2.1 million. As of today, our cash on hand is $1.8 million. In total, we have raised $13.8 million comprised of $8.8 million received in cash, and $5 million of our convertible note delivered to Cellularity to fund the acquisition and to provide the business with working capital. The first quarter does not include any revenue from our acquisition. In the second quarter, we have already seen sales from Silly George normalize and recover, and we will begin accounting for revenue from our acquisition for about half of the second quarter. The financing for BioNX was led by Sequence LifeScience, with a $5.5 million investment that not only strengthened the financing structure of the transaction, but also aligns us with a partner that enhances our capabilities across manufacturing, product development, and distribution.
Frequently Asked Questions About NXGL
When is Nexgel's next earnings date?
Nexgel's next earnings report is expected for Mar 29, 2027.
Did NXGL beat earnings estimates last quarter?
Yes. Nexgel reported EPS of -$1.60 for the quarter ended Sep 30, 2026, above the -$4.80 estimate, a 66.67% surprise.
What EPS do analysts expect from NXGL next quarter?
The consensus EPS estimate for Nexgel for the quarter ending Dec 31, 2026 is -$4.08 from 3 analysts.
How often does NXGL beat earnings estimates?
Nexgel beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -82.83%.
NXGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors